Leafwell’s Post

Join us for an engaging webinar on the world of Digital Health Technology (DHT)! On November 10th, Nicole DuPont Latimer will be joined by Shaheen E Lakhan, MD, PhD, FAAN of Click Therapeutics, Inc., Bob Schafer of Lumos Labs (Lumosity) and John Wagner, MD, PhD of Koneksa for a panel discussion that you won’t want to miss. Save your spot today! https://bit.ly/4723CaH In this webinar, you will: ✅ Grasp the fundamental elements of a successful DHT trial ✅ Navigate the intricate world of DHT research regulations ✅ Learn about choosing the right partners for your journey ✅ Confront potential challenges in DHT trials and discover strategies for adjustments

Discover #IQVIA's Visualise Healthcare Data (VHD) tool for creating and visualising healthcare insights by clinical condition, procedure, specialty, and geography. Our new factsheet showcases how VHD is a distinct solution that incorporates a range of metrics to highlight variations in demand, capacity, and clinical practice across England. Download it now to see how VHD can benefit your healthcare analysis: https://bit.ly/3QiwQMs

🌍 Real-world data (RWD)  With the rise of data-driven approaches in healthcare, understanding the real-world implications of RWD is paramount. How does it contrast with clinical trials? As we navigate the changing landscape of COVID-19, NICE has swiftly integrated RWD-informed rolling appraisals to keep pace. How can this approach be scaled up to strengthen the speed and impact of NICE’s work? Join this insightful discussion to explore: 🔸 The difference between RWD and clinical trial results 🔸 How RWD is shaping the future of drug development 🔸 Strategies for amplifying the efficiency and impact of NICE's work in response to evolving health challenges. Chair: 🔹 Dr Páll Jónsson, programme director for data and real-world evidence, NICE Speakers: 🔸 Dr Janet Valentine, executive director, Innovation and Research Policy, ABPI 🔸 Dr Arun Sujenthiran MD, clinical lead and senior medical director, Flatiron Health UK 🔸 Dr Jacoline Bouvy, programme director – medicines evaluation, NICE Connect with experts, gain valuable insights, and navigate the potential pathways for healthcare innovation using RWD. Register now at bit.ly/44kHZl8 📌 NICE - National Institute for Health and Care Excellence #NICEConf23 #PartnerContent #NHS

Had a wonderful time (as always) at the Oregon Bioscience Incubator and OTRADI monthly meetup last night. It was an especially informative session thanks to the panel discussion on Bioethics and Healthcare Decisions. A very engaged and thoughtful discussion with doctors Ruchi Thanawala, Murtaza Batla and William Hersh, MD. A key observation for me was the challenge practitioners face today as patients (admirably) do research to be better informed. In today's information age, practitioners encounter three main types of information when interacting with patients: * Information - True facts * Misinformation - Well-intentioned, but incorrect information * Disinformation - False facts spread on purpose I imagine it is especially challenging here in the U.S. where we are one of just two countries which allow direct-to-consumer drug ads on t.v. and other media. Do the people who see those ads critically evaluate them, comparing the improvements over a placebo? Add to that the misinformation and disinformation on the web and I can see it straining the ability of the provider to do the best for their patient. While the interplay of information trio is not unique to healthcare, its direct impact on patient health significantly heightens the challenge.

Communicating data results are critical to your #biopharma’s long-term success but planning for a readout can be complicated and overwhelming. In MedCity News' latest #MedCityInfluencers article, #MacDougall Managing Director Megan Prock McGrath shares a step-by-step guide on how to effectively leverage clinical trial readouts to signal progress to key stakeholders and set your company up for future clinical development milestones. Check it out: bit.ly/3SzSdJC

For an early-stage #biotech data readouts carry big risks and potential rewards. Whether providing proof of concept, proving safety and tolerability, or clearing the way for final regulatory approval, clinical trial readouts are critical de-risking events. Communicating a clear, consistent message to your audiences is crucial to success, no matter what the data show. Read my step-by-step guide in MedCity News on how to effectively leverage clinical trial readouts. bit.ly/3SzSdJC

Improve health care decision-making, patient outcomes, and access. Learn more and register for the 3rd Real World Evidence and Market Access Summit: https://lnkd.in/ef-2Y5-4

Valuable pharma thought leadership insight on a topic that will forever be relevant in the industry...

Are you curious about how data is gathered in clinical trials, including decentralized trials? At CliniLink Health, our process begins when patients and volunteers opt to participate in our studies. We meticulously collect and analyze data from their enrollment through every trial phase. At CliniLink Health, our detailed approach involves gathering data at various stages, from target and recruiting phases to pre-marketing, and through patient engagement during trials. This data is not just crucial, it's the lifeblood of our research. It's what allows us to pinpoint areas of focus for sponsors, such as understanding why Site A experiences more dropouts compared to Site B, despite being in the same geographic area. Join CliniLink Health and contribute to groundbreaking medical research. Your participation drives scientific advancements and shapes the future of healthcare. Be a catalyst for change! Visit https://lnkd.in/eSG9eYRa to discover more about our initiatives. #clinilinkhealth #CliniLink #clinicaltrials #HealthcareResearch #clinicalresearch #DataCollection #HealthcareInnovation #InclusivityMatters